Metronidazole, a nitroimidazole compound with antibacterial and antiprotozoal effects, was initially used nearly 60 years ago to treat Trichomonas vaginalis infection.1 Metronidazole is now considered first-line treatment in the United States for anaerobic bacterial infections, including bacterial vaginosis (BV).2 However, with the widespread use of metronidazole, data on the clinical and microbiologic resistance of various bacteria and parasites to this agent continue to emerge.3
Most recent to the U.S. market is secnidazole (Solosec®). Although secnidazole is new to the U.S., published data on its use in treating trichomoniasis, giardiasis, and hepatic and intestinal amebiasis, and then BV, first emerged in 1976.6 Secnidazole was found to be as active as metronidazole against trichomoniasis and amebiasis, and it persisted longer in the bloodstream than did metronidazole and tinidazole.6 In 1978, published data supported the efficacy of a single 2-g dose of secnidazole in the treatment of urogenital trichomoniasis.7 In the clinical portion of this tandem clinical and laboratory study of 140 subjects, the cure rate was 97% and tolerability was confirmed. Laboratory analysis on human subjects proved secnidazole similar to tinidazole in various pharmacokinetic properties.
According to a review article published in 1996, secnidazole was found to be rapidly and completely absorbed following oral administration.8 Because of its longer terminal elimination half-life, single-dose secnidazole was found to be superior to other nitroimidazoles in the treatment of trichomoniasis and equal to metronidazole and tinidazole in the treatment of amoebiasis and giardiasis. Except for mild gastrointestinal upset, secnidazole was considered well tolerated. Side effects of secnidazole did not typically require intervention or discontinuation. Much more recent data have supported the safety and tolerability of secnidazole 2 g in the treatment of BV.9
The CDC published its most recent sexually transmitted infection treatment guidelines in 2015,2 prior to FDA approval of Solosec in 2017. As such, many U.S. healthcare providers remain unfamiliar with secnidazole. However, a plethora of published evidence spanning more than 5 decades supports the safety and efficacy of this agent in treating a variety of infections. Although secnidazole is FDA approved only for BV at present, future indications may be on the horizon.
Kecia Harris has more than 15 years’ experience in infectious diseases, women’s health, and chronic disease research and education. She works at Syneos Health exclusively supporting Lupin Pharmaceuticals to bring emerging research related to the vaginal microbiome and dysbiosis to the forefront. She states that she is the Founder and Principal Manager of KD2 Consultants, LLC, a company focused on increasing knowledge around emerging health issues and policies for patients, government, and health and medical organizations. She is a Fellow of ISSWSH and the American Society of Sex Educators, Counselors and Therapists.
1. Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet. 1999;36(5):353-373.
2. CDC. Sexually Transmitted Diseases Treatment Guidelines. MMWR Recomm Rep. 2015;64(RR-03):1-137.
3. Doron SI, Beaulac KR, Dhand A, Snydman DR. Mechanisms of resistance in metronidazole. In: Mayers DL, Sobel JD. Antimicrobial Drug Resistance: Mechanisms of Drug Resistance, Volume 1. Cham, Switzerland: Springer; 2017:281-287.
4. Rossignol JF, Maisonneuve H, Cho YW. Nitroimidazoles in the treatment of trichomoniasis, giardiasis, and amebiasis. Int J Clin Pharmacol Ther Toxicol. 1984;22(2):63-72.
5. Petrina MAB, Cosentino LA, Rabe LK, Hillier SL. Susceptibility of bacterial vaginosis (BV)-associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin. Anaerobe. 2017;47:115-119.
6. Benazet F, Guillaume L. Amoebecide and trichomonacide activities of secnidazole in the laboratory. Bull Soc Pathol Exot Filiales. 1976;69(4):309-319.
7. Videau D, Niel G, Siboulet A, Catalan F. Secnidazole. A 5-nitroimidazole derivative with a long half-life. Br J Vener Dis. 1978;54(2):77-80.
8. Gillis JC, Wiseman LR. Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs. 1996;51(4):621-638.
9. Chavoustie SE, Gersten JK, Samuel MJ, Schwebke JR. A phase 3, multicenter, prospective, open-label study to evaluate the safety of a single dose of secnidazole 2 g for the treatment of women and postmenarchal adolescent girls with bacterial vaginosis. J Womens Health (Larchmt). 2018;27(4):492-497.
10. Parajuli B, Kimble-Hill AC, Khanna M, et al. Discovery of novel regulators of aldehyde dehydrogenase isoenzymes. Chem Biol Interact. 2011;191(1-3):153-158.
11. Solosec prescribing information. Symbiomix Therapeutics, LLC (A Lupin Company); 2017. dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=551e43d5-f700-4d6e-8029-026f8a8932ff&type=display